Meeting
2016 Genitourinary Cancers Symposium
COXEN prediction of antineoplastic drug sensitivity in bladder cancer patients.
Authors
Shalin Kothari
SUNY Upstate Medical University, Syracuse, NY
Shalin Kothari , Daniel Gustafson , Keith Killian , James Costello , Daniel C. Edelman , Jennifer Walling , Paul S. Meltzer , Dan Theodorescu , Andrea B. Apolo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 365)
DOI
10.1200/jco.2016.34.2_suppl.365
Abstract #
365
Poster Bd #
E22
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).
First Author: Philippe Barthelemy
Poster
2023 ASCO Genitourinary Cancers Symposium
FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study.
First Author: Srikala S. Sridhar
Poster
2022 ASCO Genitourinary Cancers Symposium
Outcomes according to histological variants of urothelial carcinoma after neoadjuvant chemotherapy in the GETUG-AFU V05 VESPER trial.
First Author: Yves Allory
Poster
2020 Genitourinary Cancers Symposium
Safety and efficacy of neoadjuvant chemotherapy (NAC) with accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (aMVAC) in patients (pts) with muscle invasive bladder cancer (MIBC) as a function of age.
First Author: Matthew R. Zibelman